medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-10-100-103medsovet-1133Research ArticleПрактикаPracticeПробиотик Риофлора Баланс Нео и антихеликобактерная терапия – повышение эффективности лечения за счет снижения нежелательных явленийRioFlora Balance Neo probiotic and anti-Helicobacter therapy: achieving greater treatment efficiency by reducing side effectsЛиИ. А.LeeI. A.noemail@neicon.ruСильвестроваС. Ю.SilvestrovaS. Y.noemail@neicon.ruДроздовВ. Н.DrozdovV. N.noemail@neicon.ruЦНИИ гастроэнтерологии, МоскваРоссияResearch Institute of Gastroenterology, MoscowRussian Federation201330122013010100103Copyright © Ли И.А., Сильвестрова С.Ю., Дроздов В.Н., 20132013Ли И.А., Сильвестрова С.Ю., Дроздов В.Н.Lee I.A., Silvestrova S.Y., Drozdov V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1133

Лечение язвенной болезни по современным стандартам у подавляющего числа пациентов требует эрадикационной терапии Helicobacter pylori. Современные антибиотики позволяют добиваться высокой степени эрадикации, однако клиническая эффективность лечения определяется не только эффективностью эрадикации, эпителизацией язвенного дефекта, купированием других симптомов заболевания и прогнозом, но и отсутствием нежелательных явлений возникающих в результате проводимой терапии.

According to current standards, treatment of peptic ulcer disease in a majority of patients requires eradication of Helicobacter pylori. Latest antibiotics can achieve a high degree of eradication; however, clinical efficacy of treatment is determined not only by the effectiveness of eradication, epithelization of the ulcer, elimination of other symptoms of the disease, and the prognosis, but also by absence of side effects of the treatment.

язвенная болезньHelicobacter pyloriэрадикационная терапияантибиотикиингибиторы протонной помпыpeptic ulcerHelicobacter pylorieradication therapyantibioticsproton pump inhibitorsReferencesH. pylori resistance and management strategies. World Congress of Gastroenterology. Montreal, 2005.H. pylori resistance and management strategies. World Congress of Gastroenterology. Montreal, 2005.Maastricht–3 Guidelines for Helicobacter pylori infection. 13. United European Gastroenterology Week. Copenhagen, 2005.Maastricht–3 Guidelines for Helicobacter pylori infection. 13. United European Gastroenterology Week. Copenhagen, 2005.Ардатская М.Д., Минушкин О.Н., Иконников Н.С. Дисбактериоз кишечника: понятие, диагностические подходы и пути коррекции. Возможности и преимущества биохимического исследования кала. Пособие для врачей. М., 2004.Ардатская М.Д., Минушкин О.Н., Иконников Н.С. Дисбактериоз кишечника: понятие, диагностические подходы и пути коррекции. Возможности и преимущества биохимического исследования кала. Пособие для врачей. М., 2004.Shindo K., Machida M., Fukumura M., Koide K., Yamazaki R. Omeprazole induces altered bile acid metabolism // Gut. 266. 1998. №42. Р. 266–271.Shindo K., Machida M., Fukumura M., Koide K., Yamazaki R. Omeprazole induces altered bile acid metabolism // Gut. 266. 1998. №42. Р. 266–271.Brummer R.J., Stockbrger R.W.. Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24–hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer // Dig. Dis. Sci. 1996. №41(10). Р. 2048–2054.Brummer R.J., Stockbrger R.W.. Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24–hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer // Dig. Dis. Sci. 1996. №41(10). Р. 2048–2054.Stark С.А., Adamsson I., Edlund C., Sjosted S. et al. Effects of omeprazole and amoxycillin on the human oral and gastrointestinal mic-roflora in patients with Helicobacter pylori infection // Journal of Antimicrobial Chemotherapy. 1996.№38. Р. 927–939.Stark С.А., Adamsson I., Edlund C., Sjosted S. et al. Effects of omeprazole and amoxycillin on the human oral and gastrointestinal mic-roflora in patients with Helicobacter pylori infection // Journal of Antimicrobial Chemotherapy. 1996.№38. Р. 927–939.Verdu E., Viani F., Armstrong D. et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N–nitroso compounds // Gut. 1994. №35. Р. 455–460.Verdu E., Viani F., Armstrong D. et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N–nitroso compounds // Gut. 1994. №35. Р. 455–460.Златкина А.Р. Фармакотерапия хронических болезней органов пищеварения. М.: Медицина, 1998.Златкина А.Р. Фармакотерапия хронических болезней органов пищеварения. М.: Медицина, 1998.Adamsson I., Nord C.E., Lindquist P., Sj stedt S. et al. Comparative effects of omeprazole, amoxicillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole in the oral, gastric and intestinal microflora in Helicobacter pylori–infected patients // Journal of Antimicrobial Chemotherapy. 1999. №44(5). Р. 629–640.Adamsson I., Nord C.E., Lindquist P., Sj stedt S. et al. Comparative effects of omeprazole, amoxicillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole in the oral, gastric and intestinal microflora in Helicobacter pylori–infected patients // Journal of Antimicrobial Chemotherapy. 1999. №44(5). Р. 629–640.Sjlund M., Wreiber K., Andersson K. et al. Long–Term Persistence of Resistant Enterococcus Species after Antibiotics To Eradicate Helicobacter pylori // Ann. Intern. Med. 2003. №139. Р. 483–487.Sjlund M., Wreiber K., Andersson K. et al. Long–Term Persistence of Resistant Enterococcus Species after Antibiotics To Eradicate Helicobacter pylori // Ann. Intern. Med. 2003. №139. Р. 483–487.Skinner–Adams T., Davis T.M. Synergistic in vitro antimalarial activity of omeprazole and quinine // Antimicrob. Agents Chemother. 1999. №43(5). Р. 1304–1306.Skinner–Adams T., Davis T.M. Synergistic in vitro antimalarial activity of omeprazole and quinine // Antimicrob. Agents Chemother. 1999. №43(5). Р. 1304–1306.Archer S.Y., Meng S., Shei A. et al. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells // Proc. Natl. Acad. Sci. USA. 1998. №95. Р. 6791–6796.Archer S.Y., Meng S., Shei A. et al. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells // Proc. Natl. Acad. Sci. USA. 1998. №95. Р. 6791–6796.Hague A., Diaz G.D., Hicks D.J. et al. Bcl-2 and bak may play a pivotal role in sodium butyrate – induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis // Int. J. Cancer. 1997. №72. Р. 898–905.Hague A., Diaz G.D., Hicks D.J. et al. Bcl-2 and bak may play a pivotal role in sodium butyrate – induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis // Int. J. Cancer. 1997. №72. Р. 898–905.Mariadason J.M., Velcich A., Wilson A.J. et al. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation // Gastroenterology. 2001. №120. Р. 889–899.Mariadason J.M., Velcich A., Wilson A.J. et al. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation // Gastroenterology. 2001. №120. Р. 889–899.Hague A., Elder D.J., Hicks D.J. et al. Apoptosis in colorectal tumor cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate // Int. J. Cancer. 1995. №60. Р. 400–406.Hague A., Elder D.J., Hicks D.J. et al. Apoptosis in colorectal tumor cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate // Int. J. Cancer. 1995. №60. Р. 400–406.

The authors declare that there are no conflicts of interest present.